Study of the protective effects of cyanocobalamin on methotrexate induced nephrotoxicity in rats [version 2; peer review: 2 approved]

Rana Q. Abdulwahhab, Samara Muwafaq Ali Alabdali
Pharmacology, College of Medicine, University of Baghdad, Baghdad, Adhamiya, 00964, Iraq

Abstract

Background: Methotrexate (MTX) is a chemotherapeutic drug, used mainly in many cancerous stages, inflammatory and auto-immune diseases, but its use has been limited by its nephrotoxicity. Cyanocobalamin is a water-soluble vitamin possessing nephroprotective properties. The aim of this study was to investigate the effect of cyanocobalamin on the nephrotoxicity of methotrexate.

Methods: In this study 42 albino adult female rats were used, divided into six groups each containing seven rats (n=7). First group: Control group (Negative control), 7 rats were injected intraperitoneally with 0.5ml/kg/day NS. Second group: 7 rats were injected intraperitoneal with a single dose of methotrexate (20 mg/kg) for 4 days. Third Group: 7 rats were given intraperitoneal cyanocobalamin at a dose (1.5 mg/kg/day) for two weeks, fourth, fifth, sixth group: 7 rats from each group were injected intraperitoneal with different concentrations of cyanocobalamin (0.5, 1, 1.5 mg/kg /day) respectively for two weeks and MTX (20 mg/kg) which was injected only on day 11. On day 15, rats from all groups were euthanized, and blood samples were taken for biochemical tests, including evaluating serum urea and creatinine. The kidneys were extracted for histological investigation and evaluation of antioxidant (GSH) and oxidative stress (MDA) by using kidney tissue homogenates.

Results: This study revealed that kidney damage produced by the MTX (group II) is manifested by significantly elevated (P<0.05) urea and creatinine. On the contrary, the cyanocobalamin groups (IV, V, VI) significantly (P<0.05) reduced urea and creatinine. Renal antioxidant defense systems, such as reduced glutathione depleted by MTX therapy, were restored to normal levels by cyanocobalamin. Furthermore, cyanocobalamin reduced oxidative stress (MDA) and histologically reduced renal tissue injury induced by MTX.

Conclusions: In conclusion, the study revealed that cyanocobalamin has a nephroprotective action upon MTX-induced renal damage in rats; cyanocobalamin may offer a protective effect, such as...
antioxidant action.

Keywords
Methotrexate, nephrotoxicity, cyanocobalamin, antioxidants, rat, histopathology

Corresponding author: Rana Q. Abdulwahhab (rana.qais1206b@comed.uobaghdad.edu.iq)
Author roles: Abdulwahhab RQ: Formal Analysis, Investigation, Writing – Original Draft Preparation, Writing – Review & Editing; Ali Alabdali SM: Data Curation, Supervision, Writing – Review & Editing
Competing interests: No competing interests were disclosed.
Grant information: The author(s) declared that no grants were involved in supporting this work.
Copyright: © 2022 Abdulwahhab RQ and Ali Alabdali SM. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
How to cite this article: Abdulwahhab RQ and Ali Alabdali SM. Study of the protective effects of cyanocobalamin on methotrexate induced nephrotoxicity in rats [version 2; peer review: 2 approved] F1000Research 2022, 11:1012 https://doi.org/10.12688/f1000research.124081.2
First published: 07 Sep 2022, 11:1012 https://doi.org/10.12688/f1000research.124081.1
Introduction

Methotrexate (MTX) is known as an antifolate drug and has been prescribed for over 60 years to treat different auto-
immune disorders\(^1\) and numerous types of cancers, also used in combination with other anticancer drugs\(^2\) and remains of
great interest for researchers all over the world.\(^2\)

However, some adverse effects including nephrotoxicity triggered by MTX are severe, thus, assessment of effective
drugs to overcome this problem are necessary.\(^3\)

MTX is one of the most common drugs induced nephrotoxicity when used at high doses, having molecular features that
favor crystal precipitation in the tubular lumens in a manner of slowing urine flow and decreasing urine pH.\(^4,5\)

Researchers reported that the mechanism of MTX inducing nephrotoxicity is a result of oxidative damage by the
formation of reactive oxygen species (ROS), then creating an imbalance between oxidants and antioxidants that are
responsible for the adverse effect of MTX, such as nephrotoxicity.\(^6\)

Histologically in MTX–treated rats, kidneys showed: enlargement of Bowman capsule cavity, infiltration of lympho-
cytes, diminish of glomeruli size, an increase in blood cells count and degeneration of tubules.\(^7,8\)

Like other drugs with nephrotoxic effects, MTX-induced renal function declination is clinically tested by observation of
hematuria and deterioration in serum urea and creatinine level. Reproduction of such effects is done in research studies in
animals after a single dose of MTX.\(^9\)

Many studies show that dietary antioxidants play a role in the protection of the kidney against MTX-induced
nephrotoxicity.\(^6\)

Cyanocobalamin is considered a synthetic compound of vitamin B12. Vitamin B12 is known as a water-soluble vitamin
which is synthesized by microorganisms in nature, and in the chemical aspect it is related to a class known as corrinoids.
This name is derived from the cyanide group that is attached to molecule.\(^10\)

Furthermore, vitamin B12 has several functions in methylation reactions in the body, that acts as a cofactor in the form of
methylcobalamin by the conversion of homocysteine to methionine and in the form of adenosylcobalamin in the
transformation of methylmalonyl-CoA to succinyl-CoA. Both of these chemical reactions are important for cell division
and growth,\(^11\) in addition vitamin B12 plays a role in erythropoiesis and healthy neurological functions,\(^12\) and it proved
useful in the treatment of many diseases associated with inflammatory and oxidative stress.\(^13\)

The FDA have stated that cyanocobalamin is safe, there is no toxicity reported when cyanocobalamin given to animals,
even at several thousand times their nutritional requirements.\(^14\)

In this study, vit B12 was selected due to antioxidant action according to previous animal studies, in which vitamin B12
can lower oxidative stress when used with different drugs such as gentamycin and tamoxifen.\(^13,15\)
Vit B12 act as anti-oxidant by different mechanism: as a direct superoxide scavenger; in addition, it may indirectly enhance ROS scavenging by protecting glutathione, which probably involves a complex network of processes that is not yet fully understood.16

The objective of this study is to determine the protective effects of cyanocobalamin administration on methotrexate-induced nephrotoxicity in rats using biochemical and histopathological studies in renal tissue of rats.

**Methods**

**Ethical approval**

We have received ethical approval for work on experimental animals from the **Researcher Ethics Committees** at Department of Pharmacology and College of Medicine/University of Baghdad. On 7 November 2021 via ethical letter (approval number 1455). This study is reported in line with the ARRIVE guidelines.40

**Chemicals**

All chemicals used in this experimental study were of the highest available purity, and no purification was necessary. Vitamin B12 GERDA (1000 mcg/4 ml) (GERDA®1000, batch: H060) was purchased from GERDA, France. Methotrexate ampule (50 mg/2 ml) Methotrexate Mylan 50 mg/2 ml (batch/LOT 5103) was purchased from Mylan – Merck generiques, Italy, pellet food patch number 3218 from Mazuri food pellets (Mazuri Primate Diet, Special Diet Foods Ltd., UK).

**Experimental animals**

The study was carried out on 42 adult female albino rats. The sample size of n=7 per group was calculated based on previous research, inclusion criteria include (ages ranged from 2-3 months, sex: female and body weight ranged from 150-250 grams. In this study there was no exclusion criteria, the animals used were obtained from the same source, at the same time, there is no previous procedure performed on these rats before the experimental study.

The rats were obtained from the Animal House of the Iraqi center of cancer and genetic research/Almustansria University. They remained for one week to be adapted without intervention in a climate-controlled environment with appropriate temperature (22-25 c) and synthetic 12:12 hours in the light-dark cycle, rats received pellet food and tap water/ad libitum.

The human care of the animals was according to international guidelines for the care and use of laboratory animals. All of these efforts were made to reduce the number of rats and their suffering. These efforts included: 1. constant checking of animal house air conditioning with a standard free access to tap water/ad libitum; 2. cleaning the animal house and cages; 3. During the experiment careful handling was given into account and injection dose of the drug was as quickly as possible and given the dose to each rat separated from other; 4. used the effective anesthetic dose.

When the period of adaptation was over, the weight of the rats was recorded and they were randomly divided and placed in one cage per group, the name of the group was then recorded in each cage.

In total, 42 rats were randomly (simple randomization) divided into six group (n=7). All groups of animal treated in the same house under same environment. The experimental procedure was done blindly, daily between 8 am -12 pm for 15 days.

Six animal groups were made in this study (7 animals/each group) as follows:

**Group I** (control): 7 rats were treated with 0.5 ml normal saline once daily by intraperitoneal (I.P.) injection for 14 days and it was served as negative control.

**Group II (MTX):** 7 rats were treated with a single IP dose of methotrexate (MTX) (20 mg/kg) followed by single IP injection of 0.5 ml normal saline for 4 days. This group was served as positive control.17

**Group III (1.5 mg of vit B12):** 7 rats were treated with vitamin B12 (1.5 mg/kg/rat/day) once daily by I.P. for two weeks.

**Group IV (0.5 mg vit B12 +MTX):** 7 rats were treated with vitamin B12 (0.5 mg/kg/rat/day) once daily by I.P. for two weeks + 20 mg/kg I.P. of MTX injected only at day 11.18

**Group V (1 mg vit B12 +MTX):** 7 rats were treated with vitamin B12 (1 mg/kg/rat/day) once daily by I.P. for two week + 20 mg/kg I.P. of MTX injected only at day 11.
Group VI (1.5 mg vit B12 +MTX): 7 rats were treated with vitamin B12 (1.5 mg/kg/rat/day) once daily by I.P. for two weeks + 20 mg/kg by I.P. of MTX injected only at day 11.

At the end of this experiment and on day 15 the rats were euthanized by the use of xylazine (10 mg/kg) and ketamine (75 mg/kg) both are commonly used for this purpose (this is followed by the ethical standards and ARRIVE guidelines, and this type of euthanization is normally performed in most acute toxicity tests). Kidney tissue samples were taken for biochemical and histopathological studies.

Sample collection and tissue preparation
After euthanasia of the animals, blood was collected by intracardiac puncture. The clot was isolated with a glass rod and then centrifuged (CGOLDENWALL 80-2 Electric Lab Centrifuge) at 3000 rpm for 15 minutes, the supernatant was used to evaluate urea and creatinine as parameters of kidney function. The abdomen was cut with a scalpel blade, then the kidney was extracted and stored in 10% formalin (Pan Reac APPIChem, Cat NO:A0877.100).

A small portion of the kidney was cut and weighed on an electrical weighing scale (Redwag, model: AS220.R1). A sample of almost 0.4 gram weight was converted to homogenizer (Omni TH, Cat NO, 51-001) and mixed with 1 ml of ice cold phosphate buffered saline and centrifuged for 15 minutes at 5000 rpm. Subsequently, the resulting supernatant was isolated and stored at -20°C until used for the determination of the MDA and GSH biomarkers.

Investigated parameters
Histological examination of the kidneys
Histopathological studies were performed, kidney tissue samples were fixed in 10% formalin, then graded in ethanol, dehydrated, and embedded in paraffin. Kidney sections were cut with a microtome (HHQ-1508R Rotary Microtome, China) set at a thickness of 3-4 μm; mounted on clear glass, then the kidney tissue was stained with Hematoxylin and Eosin (H&E). Then the kidney tissue sections were examined and evaluated by the histopathologist using light microscopy at 10× and 40× (Viola Mc 20i, Micros® Austria). An overall score of the severity of damage to kidney tissue was assessed in stained tissue sections by scoring each of the following histopathological observations:
A. congestion of glomeruli B. congestion of interstitial C. cast and degeneration D. Inflammatory cell infiltrate E. Increased urinary space F. Inflammation of the Pelvicalyceal area.

Where, 0=none (no damage); 1=mild; 2=moderate; 3=severe. A total of field of section was examined for all animals in each group.

Serum analysis
Determination of serum creatinine and urea level
The quantitative assay of creatinine using the jaffe method was used. The quantitative assay of creatinine by the jaffe method is based on the reaction of creatinine with sodium picrate. Creatinine reacts with alkaline picrate forming a red-color complex. The intensity of the formed color is proportional to the creatinine concentration within the sample and the creatinine level can be calculated by measuring the absorbance at 490 nm. This method was performed using a creatinine kit (Cat. NO D500, Spinreact, Espana), while urea was measured quantitatively using the enzyme method described below, using a urea kit (Cat.NO p406, Spinreact, Espana).

Enzymatic method
Quantitative determination of serum urea depend on enzymatic reaction in which the urea within the sample is hydrolyzed enzymatically into ammonia (NH4 +) and carbon dioxide (CO2). Ammonia ions formed reacts with α-ketoglutarate in a reaction catalyzed by glutamate dehydrogenase (GLDH) with simultaneous oxidation of NADH to NAD+:

The decrease in NADH concentration is proportional to the concentration of urea within the samples, and the level of urea can be calculated by measuring the absorbance at 340 nm. Calculation of urea (mg/dl) within serum samples = \( \Delta A \) Sample \( \times \) 50 (Standard conc.) = mg/dL urea in the sample.

Determination of malondialdehyde (MDA) and reduced glutathione (GSH) within the kidney homogenate of the rat
Malondialdehyde and reduced glutathione levels were measured by the enzyme-linked immunosorbent assay (ELISA) sandwich technique.
The MDA content in the kidney tissue homogenate was quantitatively estimated by the MDA kit based on the ELISA method according to the manufacturer's instructions (Cat. No. E0156Ra, Bioassay Technology Laboratory, China) and Rat reduced glutathione ELISA kit (Cat. No E1443Ra, Bioassay technology laboratory, China), as written on the manufacturing protocol.

The content of MDA and GSH in kidney tissue homogenate samples can be measured by comparing the optical density of the samples, with the standard curve. Level of MDA is expressed as nmol/mL, and level of GSH is expressed in Ng/ml.

**Elisa MDA kit procedure**

Preparation was done to all reagents and chemicals to kit in the kit box (and stored at room temperature, then 40 μl sample added to sample wells and after that add 10 μl anti-MDA antibody to sample wells, then 50 μl streptavidin-HRP to sample wells. Then mixed them well and Incubated for 60 minutes at 37°C. The sealer was removed and the plate was cleaned 5 times with washing buffer. Then the product was placed in automated washing (biotek® ELX 600-biotek Co., – USA), then the absorption of the plate was determined using Elisa reader equipment (biotek® ELX 600-biotek Co., – USA) the absorption is directly proportional to the concentration, which is then estimated by comparing the reading with the control group.

**GSH procedure**

This was the same as the MDA procedure.

**Statistical analysis**

Data was expressed statistically as the mean±SEM, (standard error of mean) and the significance of the differences among various groups was decided by one-way analysis of variance (ANOVA), then by least significant difference (LSD) test. The statistical package for the social sciences (SPSS) version 26 was used. Differences were deemed statistically significant at the P-value less than 0.05 level.24

**Results**

**Effect of cyanocobalamin on GSH contents within kidney tissue homogenate of rats**

A non-significant difference was observed between the cyanocobalamin (group III) and control groups (group I).37

While the level of GSH in the renal tissue homogenate significantly increased (P<0.05) in both groups IV and V, it was highly significantly increased in group VI compared to the group treated with MTX treated group (P<0.01) as shown in Figure 1.

**Effect of cyanocobalamin on Malondialdehyde (MDA) Levels within the kidney tissue homogenate of rat**

Table 1 and Figure 2 show that, the MDA level was significantly (P<0.05) elevated in the methotrexate group (II) compared to the control (group I) and cobalamin (group III).

Non-significant differences were detected among the cyanocobalamin (group III) and control groups (group I).

Although MDA levels in renal tissue homogenate (P<0.05) significantly decrease in the IV & V groups, and highly significant decrease in group VI compared to the MTX treated group (P<0.01).

---

**Figure 1.** Showing the effect of cyanocobalamin on glutathione (GSH) contents in the kidney tissue homog-enate of rats.

- Each value represents mean ± standard error of means (SEM) (N=7/Group),
- Values expressed in non-identical letters (a, b, c, d) are significantly difference (P<0.05),
- *Highly significant difference from MTX P<0.01.
Effect of cyanocobalamin on plasma urea (U) and creatinine (CR) level

Table 2 and Figures 3 & 4 showed that the methotrexate-treated rat group (II) produced a significant elevation (P<0.05) of the plasma level of urea and creatinine, compared to the corresponding levels of the control group (I) and the cobalamin group (III).

Non-significant difference (P>0.05) of the serum of urea and creatinine was found between the control group (I) and cobalamin group (III).

Table 1. Effect of cyanocobalamin on levels of malondialdehyde (MDA) and glutathione (GSH) within the kidney tissue homogenate of rats.

| Group | N=7/group | Malondialdehyde (MDA) nmol/ml | Glutathione Ng/ml |
|-------|-----------|-------------------------------|------------------|
| Group I (control) | /I.P. injected with 0.5 ml/kg/day normal saline | 0.57829±0.038840<sup>a</sup> | 8.53457±0.411815<sup>a</sup> |
| Group II/MTX I.P. 20 mg/kg | | 2.30229±0.208563<sup>b</sup> | 4.35600±0.224845<sup>b</sup> |
| Group III/B12 1.5 mg/kg for 14 days | | 0.64900±0.049109<sup>a</sup> | 7.87243±0.396563<sup>a</sup> |
| Group IV (20 mg of MTX +0.5 mg/kg of VIT B12 for 14 days) | | 1.72586±0.285667<sup>c</sup> | 5.55929±0.308215<sup>c</sup> |
| Group V (20 mg of MTX +1 mg/kg of VIT B12 for 14 days) | | 1.70429±0.211100<sup>c</sup> | 5.59300±0.463932<sup>c</sup> |
| Group VI (20 mg/kg of MTX +1.5 mg/kg of vit b12 for 14 days) | | 1.16757±0.077618<sup>cd</sup> | 6.77829±0.414523<sup>cd</sup> |

Each value represents the mean ± standard error of the means (SEM) (N=7/Group). Values expressed in non-identical letters (a, b, c, d) are significantly different (P<0.05).

*Highly significant difference from MTX P<0.01.

Figure 2. Showing effect of cyanocobalamin on malondialdehyde (MDA) contents in the kidney tissue homogenate of rats.

- Each value represents mean ± standard error of means (SEM) (N=7/Group),
- Values expressed in non-identical letters (a, b, c, d) are significantly different (P<0.05),
- *Highly significant difference from MTX P<0.01.

Effect of cyanocobalamin on plasma urea (U) and creatinine (CR) level

Table 2 and Figures 3 & 4 showed that the methotrexate-treated rat group (II) produced a significant elevation (P<0.05) of the plasma level of urea and creatinine, compared to the corresponding levels of the control group (I) and the cobalamin group (III).

Non-significant difference (P>0.05) of the serum of urea and creatinine was found between the control group (I) and cobalamin group (III).

Table 2. Effect of cyanocobalamin on plasma urea and creatinine level.

| Group | N=7/group | Urea mg/dl | Creatinine mg/dl |
|-------|-----------|------------|------------------|
| Group I (control) | /I.P. injected with 0.5 ml/kg/day normal saline | 33.557±0.9198<sup>a</sup> | 0.586±0.0340<sup>a</sup> |
| Group II/MTX I.P. 20 mg/kg | | 48.071±1.4276<sup>b</sup> | 1.657±0.0685<sup>b</sup> |
| Group III/B12 1.5 mg/kg for 14 days | | 35.757±0.5871<sup>a</sup> | 0.653±0.0706<sup>a</sup> |
| Group IV (20 mg of MTX +0.5 mg/kg of VIT B12 for 14 days) | | 45.143±0.5084<sup>c</sup> | 1.429±0.0522<sup>c</sup> |
| Group V (20 mg of MTX +1 mg/kg of VIT B12 for 14 days) | | 44.286±1.0169<sup>c</sup> | 1.390±0.0879<sup>c</sup> |
| Group VI (20 mg/kg of MTX +1.5 mg/kg of vit b12 for 14 days) | | 38.886±1.1365<sup>cd</sup> | 0.864±0.1036<sup>cd</sup> |

Each value represents mean ± standard error of means (SEM) (N=7/Group). Values expressed in non-identical letters (a, b, c, d) are significantly different (P<0.05).

*Highly significant difference from MTX P<0.01.
Rats treated with different concentrations of cyanocobalamins in group IV and group V produced significantly decreased serum urea and creatinine levels ($P<0.05$), while group VI produces highly significant decreased serum urea levels compared to MTX-treated group II ($P<0.01$).

**Histological findings**

Histopathological changes were examined to assist the finding of biochemical markers.$^{38,39}$ Figure 5 showed the scoring severity of the histopathological parameters of kidney tissue (Congestion of glomeruli, Congestion of interstitial, Cast and degeneration, inflammatory cell infiltrate, increased urinary space, Inflammation of pelvicalyceal system).

There were non-significant difference ($P>0.05$) of histopathological parameters in rats kidney section of group I (CONTROL) compared to group III.

While morphological damage (histopathological) are observed within the kidney section of rats treated with MTX group II, caused significant damage ($P<0.05$) in rats kidney tissue in all histopathological parameters compared to each histopathological parameter in each of Group I, III, IV, V, VI as found in Figure 5.

Moreover, there is significant decrease in damage in all histological parameters in group IV, V, VI compared to group II.

In addition there is significant decrease in damage in all histological parameters ($P<0.05$) in the Group VI compared to Group IV and Group V.

The MTX –treated group (II) kidneys revealed obvious variations and injuries, characterized by severe congestion of both interstitial and glomeruli, moderate increased urinary space causing shrinkage in the glomerular size as shown in Figure 6B and a high number of hyaline casts in the medullary region with degeneration of tubules as shown in Figure 6C, severe inflammation of inflammatory cell infiltrate as shown in Figure 6D and pelvicalyceal system as shown in the as shown in Figure 6E in the *Extended data.*$^{39}$

---

**Figure 3.** Showing effect of cyanocobalamin on plasma urea level.
- Each value represents mean ± standard error of means (SEM) (N=7/Group),
- Values expressed in non-identical letters (a, b, c, d) are significantly difference ($P<0.05$),
- *Highly significant difference from MTX $P<0.01$.

**Figure 4.** Showing the effect of cyanocobalamin on plasma creatinine level.
- Each value represents mean ± standard error of means (SEM) (N=7/Group),
- Values expressed in non-identical letters (a, b, c, d) are significantly difference ($P<0.05$),
- *Highly significant difference from MTX $P<0.01$. 

---

Figure 3.

- Each value represents mean ± standard error of means (SEM) (N=7/Group),
- Values expressed in non-identical letters (a, b, c, d) are significantly difference ($P<0.05$),
- *Highly significant difference from MTX $P<0.01$.

Figure 4.

- Each value represents mean ± standard error of means (SEM) (N=7/Group),
- Values expressed in non-identical letters (a, b, c, d) are significantly difference ($P<0.05$),
- *Highly significant difference from MTX $P<0.01$. 

---

Figure 6.
Furthermore, the cobalamins group (group III) show a normal glomerular cellularity (no congestion) and the urinary space is within normal limits. The interstitial does not show congestion; the tubule does not show degeneration and no inflammatory infiltrate as shown in Figure 7, similar to the control group (group I), which shows a normal looking cortex; the glomeruli have normal cellularity, no capillary congestion, the urinary space is not dilated; the interstitial does not show congestion, no inflammatory infiltrate, there is no tubular cell degeneration, and no casts. The pelvicalyceal system is not shown here, as shown in Figure 6A.

Group IV showed a moderate increase in urinary space, moderate congestion of the glomeruli and interstitial as shown in Figure 8A, a moderate amount of hyaline cast formation and degeneration as shown in Figure 8B, moderate inflammation Figure 5. The histological scores of all the groups. Values are mean ±SEM for seven rats in each group, values expressed in non-identical letters (a, b, c, d) are significantly different at P value (P<0.05) (N=7).
Figure 6. (A) section of kidney control group (Group I) of rat shows a Normal looking cortex, the glomeruli are with in normal (yellow arrow) no congestion of their capillaries, the urinary space is not dilated (green arrow), and the interstitial shows no congestion (pink arrow) (H&E ×40). (B) The kidney tissue section of rat treated with methotrexate for 4 days (group II) shows severe glomeruli congestion (Yellow arrow) and atrophy with widening of the urinary space (green arrow), (green arrow), severe congestion is also observed in the interstitial (pink arrow) (H&E ×40).

Figure 7. Section of the kidney tissue of rat treated Cyanocobalamin for 14 days (Group III) show A normal glomerulus (yellow arrow) and the urinary space is within normal limits (Green arrow), the interstitial shows no congestion (Pink arrow) (H&E, ×40).

of the pelvicalyceal system Figure 8c, moderate infiltrate of inflammatory cells of the interstitial Figure 8d as shown in the Extended data.39

Group V showed a moderate increase in urinary space, moderate congestion of glomeruli and interstitial as shown in Figure 9A, moderate amount of hyaline cast in the tubular lumen and degeneration as shown in Figure 9B, moderate inflammation of the pelvicalyceal system 9C, moderate inflammatory cell infiltrate of interstitial as shown in Figure 9D as shown in the Extended data.39

Furthermore, in group VI there was a significant decrease in damage in all histopathological parameters compared to other groups (II, IV, and V). There is mild glomerular congestion and increased cellularity, the interstitial space also shows mild congestion and degeneration, mild increased urinary space as shown in Figure 10A, Few casts are seen within tubular lumens as shown in Figure 10B, mild inflammatory infiltrate in the pelvicalyceal system as shown in Figure 10c, mild inflammatory cell infiltrate of the interstitial as shown in Figure 10d in the Extended data.39
Discussion

The renal system plays a vital role in maintaining extracellular environment homeostasis, mainly detoxification and elimination of toxic drugs and their metabolites. Nephrotoxicity related to toxic medications, especially chemotherapeutic drugs are common and represents approximately 20% of all renal failure cases.15

This study focused on the protective effect of cyanocobalamin on MTX-induced renal damage in rats by reducing Cr and urea levels and repairing histopathological damage to the kidney.

The present data established that the activities of vit B12 against MTX-induced renal damage in rats could be successful by suppressing oxidative stress by reducing MDA levels and increasing GSH levels.

Figure 8. A. Section of the kidney tissue of rat (Group IV) show moderate congestion of interstitial (Pink arrow), moderate congestion of glomeruli (yellow arrow) and moderate increased of urinary space (Green arrow) (H&E, ×40). B. The section of rat kidney tissue (Group IV) shows degeneration and moderate amount of hyaline cast formation (Red arrow) (H&E, ×40).

Figure 9. A. Section of the kidney tissue of rat (Group V) Show moderate congestion of interstitial (Pink arrow), moderate congestion of glomeruli (yellow arrow) and moderate increased of urinary space (Green arrow) (H&E, ×40). B. The section of rat kidney tissue (Group V) shows a moderate tubular degeneration and a moderate formation of hyaline casts with in tubular lumens (red arrow) (H&E, ×40).
Researchers indicated the main pathway for MTX elimination by kidney. Furthermore, the administration of high doses of MTX causes higher drug concentrations in plasma and urine, at an acute and extremely toxic dose the elimination of MTX is delayed execution, then increases the serum creatinine level, and thus is one of the biomarkers of renal failure, this is consistent with the present study.25,26

Group IV, V, and VI resulted in a significant reduction (P <0.05) in plasma urea and creatinine levels, compared to those levels in group II. That is consistent with the finding of Alshanwani et al.,15 which showed that vitamin B12 improved creatinine clearance levels and renal blood flow, thus, this can reduce creatinine and blood urea nitrogen.15

MDA is highly reactive compound, is formed through the peroxidation of polyunsaturated fatty acids by the action of reactive oxygen species, as an effect of the depletion of antioxidant systems.27

In the current study, a non-significant difference was found (p >0.05) within the content of MDA of kidney tissue homogenate among the control (group I) and cyanocobalamin (group III), which is in line with a previous animal study.13

MTX treated rats (group II) demonstrated significant increases in MDA levels in group II, compared to control (group I) and cyanocobalamin (group III) which is consistent with previous studies.28,29

Increased levels of MDA in the methotrexate group might be related to oxidative stress, which likely stores the leukocyte in tissues by increasing the level of ROS.30 Active leukocytes release many chemical enzymes, such as protease, elastase, and myeloperoxidase, resulting in more free radicals.

In addition, reactive oxygen species produce changes in permeability of both endothelial and epithelial cells. It can produce tissue injury, caused by MTX-promoted OS, by interfering with unsaturated form fatty acids of cell membranes, nucleic acid and sulfhydryl bonds. MTX therapy can indirectly secrete mitochondrial enzymes that lead to damaged mitochondria, and a decrease in antioxidant action.8

In this study, groups IV, V and VI produced a significant reduction (P<0.05) in the level of MDA, compared to the group II treated with MTX.

These results are due to the antioxidant function of Cyanocobalamin by inducing the activity of methionine synthase, interacting with ROS, and avoiding glutathione.13,31
The body’s tissues contain relatively large concentrations of the reduced glutathione (GSH) peptide, a water-soluble, low-molecular-weight tripeptide made of cysteine, glutamic acid, and glycine. And it is a non-enzymatic antioxidant; preserving reduced glutathione in the cell is essential to improve the immune system and protect the body from diseases.32,33

GSH act as a reducing agent that is important for conserving enzymes and antioxidants in the form of an active state. This mechanism is important to provide protection from cytotoxic agents, free radicals, and oxidative damage.34

In this study, the MTX group (group II) produced a significant reduction in the level of GSH, compared to the control group (group I) which is in line with a previous study.3

This result may be related to the mechanism of OS generation by MTX by inhibiting cellular NADPH (nicotinamide adenine dinucleotide phosphate). Through the pentose phosphate cycle, the glutathione reductase enzyme NADPH is used as a reducing agent for cellular GSH (primary antioxidant). The reduction of cellular GSH by MTX decreased the systemic antioxidant action.35

Group IV, V, and VI produced a significant (P<0.05) raise in GSH levels compared to those levels in groups II, these effects could be explained by the fact that cyanocobalamin has antioxidant properties consistent with the findings of Padmanabhan et al., which showed that supplementation with cyanocobalamin was confirmed by increased GSH, this institutes the main intracellular antioxidant and reduces oxidative stress.34

However, histological analysis revealed that, unlike the control group (group I), the methotrexate group (group II) had destructive effects, were kidney sections of such rats showed moderate increased urinary space causing shrinkage in the glomerular size, forming a high number of hyaline casts in the medullary region, with degeneration of tubules, congestion of both interstitial and glomeruli. The glomerular show reduced cellularity, severe inflammation of the inflammatory cell infiltrate, and pelvicalyceal system. This is similar to the findings of other previous studies.7,8

The exact mechanism of MTX nephrotoxicity was unclear. However, some studies found that the main factor in MTX-related tissue injury was oxidative damage, with successive generation of more free radicals, the role of oxidative stress has been reported in MTX-induced nephrotoxicity.36

Moreover, in groups IV, V and VI, there was a significant decrease in damage in all histological parameters (Expansion of bowman space, Congestion of glomeruli, Congestion of interstitial, Cast and degeneration, Inflammatory cell infiltrate, Inflammation of pelvicalyceal system) (P<0.05), as compared to group II. These findings are similar to those of Saeed et al13; where the protective effect of vitamin B12 against nephrotoxicity was observed by histopathological examination.13

These results were considered an index of the defensive effect of cyanocobalamin on the kidney damaged by the methotrexate drug, the protective action of vitamin b12 has been previously reported in experimental studies.15

Conclusion
This study demonstrates the beneficial effects of cyanocobalamin on MTX-induced nephrotoxicity. Data suggest that the protective effect of cyanocobalamin is through the amelioration of oxidative markers (MDA) in kidney homogenate; the improvement of antioxidants (GSH), compensating for the increase in urea, creatinine, and the improvement of histopathological lesions of the kidney of rats. These results will make a new technique of protection from nephrotoxicity by MTX therapy, by administration of cyanocobalamin.

Data availability
Underlying data
Zenodo: Study in the protective effects of cyanocobalamin on Methotrexate induced Nephrotoxicity in rats. https://doi.org/10.5281/zenodo.6842130.37

This project contains the following underlying data:
- Z.xlsx (biochemical test plasma of urea and creatinine, antioxidant enzyme (GHS) and oxidative stress marker (MDA))
Zenodo: Study in the protective effects of cyanocobalamin on Methotrexate induced Nephrotoxicity in rats. https://doi.org/10.5281/zenodo.6982116.

This project contains the following underlying data:

- Histopathological score.xlsx

Extended data

Zenodo: Study in the protective effects of Cyanocobalamin on Methotrexate induced Nephrotoxicity in rats. https://doi.org/10.5281/zenodo.7008082.

This project contains the following extended data:

- Supplementary data.docx (histopathological images of kidney section of all six group (n=7))

Reporting guidelines

Zenodo: ARRIVE checklist for ‘Study in the protective effects of cyanocobalamin on Methotrexate induced nephrotoxicity in rats’. https://doi.org/10.5281/zenodo.6982116.

Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).

Acknowledgments

The authors would like to thanks department of pharmacology/college of medicine, to providing facilities to bring this study and doctor Ban A. Abdul Majeed, consultant pathologist and PhD Farah Kais Abdul-Wahab for assistance during the study.

References

1. Yan H, Su R, Xue H, et al.: Pharmacomicrobiology of Methotrexate in Rheumatoid Arthritis: Gut Microbiome as Predictor of Therapeutic Response. Front. Immunol. 2021; 12. Publisher Full Text

2. Kožmíník P, et al.: Overview of dual-acting drug methotrexate in different neurological diseases, autoimmune pathologies and cancers. Int. J. Mol. Sci. 2020; 21(10): 3483. PubMed Abstract | Publisher Full Text

3. Li Y, et al.: Dioscin ameliorates methotrexate-induced liver and kidney damages via adjusting miRNA-145-5p-mediated oxidative stress. Free Radiac. Biol. Med. 2021; 169: 99–109. PubMed Abstract | Publisher Full Text

4. Izzedine H, Perazella MA: Anticancer drug-induced acute kidney injury. Kidney Int. Rep. 2017; 2(4): 504-514. PubMed Abstract | Publisher Full Text

5. Valade S, et al.: High-dose methotrexate in ICU patients: a retrospective study. Ann. Intensive Care. 2020; 10(1): 1–5. Publisher Full Text

6. Yulsk Y, et al.: Effects of quercetin on methotrexate-induced nephrotoxicity in rats. Hum. Exp. Toxicol. 2017; 36(1): 51-61. PubMed Abstract | Publisher Full Text

7. Al-Rashidy AH, et al.: Role of erythropoietin in methotrexate-induced nephrotoxicity in adult male albino rats. J. Nephropharmacol. 2018; 7(7): 156-163. Publisher Full Text

8. Jalili C, et al.: Toxic effects of methotrexate on rat kidney recovered by crocin as a consequence of antioxidant activity and lipid peroxidation prevention. Iran. J. Biomed. 2020; 24(1): 39-46. PubMed Abstract | Publisher Full Text

9. Stojilkovic N, et al.: The encapsulation of lycopene in nanoliposomes enhances its protective potential in methotrexate-induced kidney injury model. Oxidative Med. Cell. Longev. 2018; 2018: 1-71. PubMed Abstract | Publisher Full Text

10. Derya K, Nurhan K, Ermin K, et al.: Vitamin B12 Regulates the Expression of Methotrexate-Induced Increased Markers of Autophagy: An Immunohistochemical Study. Open Acc. J. Toxicol. 2021; 4(05): 555648. PubMed Abstract | Publisher Full Text

11. Allen LH: Vitamin B-12. Adv. Nutr. (Bethesda, Md.). 2012; 3(1), 54-55. PubMed Abstract | Publisher Full Text

12. Greibe E, et al.: Dietary intake of vitamin B12 is better for restoring a low B12 status than a daily high-dose vitamin pill: An experimental study in rats. Nutrients. 2018; 10(1):1096. PubMed Abstract | Publisher Full Text

13. Hajihashemi S, et al.: Effects of cobalamin (Vitamin B12) on gentamicin induced nephrotoxicity in rat. Drug Res. 2017; 67(12): 710-718. PubMed Abstract | Publisher Full Text

14. Gabriele A, Alex B, Vasileios B, et al.: Scientific Opinion on safety and efficacy of vitamin B12 (cyanocobalamin) produced by Ensifer adhaerens when used as a feed additive for all animal species. EFSA J. 2015; 13: 1–21. PubMed Abstract | Publisher Full Text

15. Absharwani AR, et al.: Cyanocobalamin and/or calcitriol mitigate renal damage-mediated by tamoxifen in rats: Implication of caspase-3/NF-κB signaling pathways. Life Sci. 2021; 277: 119512. Publisher Full Text

16. Ghanim WK, Al-Shawi NN, Al-Moziel MS: Effects of Two Different Doses of Vitamin B2 and a Single Dose of Vitamin B12 Against Cyclophosphamide Induced Nephrotoxicity. Medico-Legal Update. 2020; 20(1): 493.

17. Yuces Y, Tabur S, Gozeneli O, et al.: The effects of lycopene on intestinal injury due to methotrexate in rats. Redox Rep. 2016; 21: 113-118. PubMed Abstract | Publisher Full Text

18. Salah R, Salama MF, Mahgoub HA, et al.: Antitumor activity of sitagliptin and vitamin B12 on Ehrlich ascites carcinoma solid tumor in mice. J. Biochem. Mol. Toxicol. 2021; 35(2): e22645. PubMed Abstract | Publisher Full Text
19. Dabak DO, Kocaman N: Effects of silymarin on methotrexate-induced nephrotoxicity in rats. Avicenna J. Phytomed. 2021; 10(3): 218–223.

20. Tamba AK, Kasaz F, Peker Akalan P, et al.: The protective effect of rutin against methotrexate-induced nephrotoxicity in rats. Turk. J. Nephrol. 2021; 30(3): 734–739.

21. Young DS: Effects of disease on clinical Lab. Tests. 4th ed. AACC; 2001.

22. Urea KA, Kaplan A, et al.: Clin Chem the C.V. Mosby Co. St Louis. Toronto. Princeton 1984; 1257-1260 and 437 and 418.

23. Dahniar S A, et al.: Effect of Brown Algae Extract Sargassum sp on Malondialdehyde Levels in White Rats (Rattus Norvegicus) Pregnant Wistar Strains. Medico Legal Update. 2020; 20(3): 822–827.

24. Abdul-Wahab FK, Al-Shawi NN: Effects of Vitamin D3 on Methotrexate-Induced Jejunum Damage in Rats. Iraqi. J. Pharm. Sci. 2020; 29(1): 260–267.

25. Osman AT, et al.: Effects of disease on clinical Lab. Tests. 4th ed. AACC; 2001.

26. Patel NN, et al.: Subacute toxicopathological studies of methotrexate in Wistar rats. Vet. World. 2014; 7(7): 489–495.

27. Kapusta A, Kuczynska B, Pupple K: Relationship between the degree of antioxidant protection and the level of malondialdehyde in high-performance Polish Holstein-Friesian cows in peak of lactation. PLoS One. 2018; 13(3): e0193552.

28. Al-Abdaly YZ, et al.: Effect of methotrexate and aspirin interaction and its relationship to oxidative stress in rats. Iraqi. J. Vet. Sci. 2021; 35(1): 151–156.

29. Moodi H, et al.: Ethanolic extract of Iris songarica rhizome attenuates methotrexate-induced liver and kidney damages in rats. Avicenna J. Phytomed. 2020; 16(4): 372–381.

30. Sener G, Ekioğlu-Demiralp E, Cetiner M, et al.: Beta-glucan ameliorates methotrexate-induced oxidative organ injury via its antioxidant and immunomodulatory effects. Eur. J. Pharmacol. 2006; 542(1-3): 170-178.

31. Salah R, et al.: Antitumor activity of sitagliptin and vitamin B12 on Ehrlich ascites carcinoma solid tumor in mice. J. Biochem. Mol. Toxicol. 2021; 35(2): e22645.

32. Bas Z: Inhibition effect of nicotinamide(vitamin B3) and reduced glutathione (GSH) peptide on angiotensin-converting enzyme activity purified from sheep kidney. Int. J. Biol. Macromol. 2021; 189: 65–71.

33. García-Sánchez A, Miranda-Díaz AG, Cardona-Muñoz EG: The role of oxidative stress in physiopathology and pharmacological treatment with pro-and antioxidant properties in chronic diseases. Oxidative Med. Cell. Longev. 2020; 2020: 1–16.

34. Çetin ES, et al.: Methotrexate-induced nephrotoxicity in rats: protective effect of mistletoe (Viscum album L.) extract. Complement. Med. Res. 2017; 24(6): 364–370.

35. Padmanabhan S, et al.: Folate/vitamin B12 supplementation combats oxidative stress-associated carcinogenesis in a rat model of colon cancer. Nutr. Cancer. 2019; 71(1): 100–110.

36. Abdulwahab RQ, Ali SM: Study in the protective effects of Cyanocobalamin treatment with pro-and antioxidant properties in chronic diseases. Oxidative Med. Cell. Longev. 2020; 2020: 1–16.

37. Abdulwahab RQ, Ali SM: Study in the protective effects of Cyanocobalamin treatment with pro-and antioxidant properties in chronic diseases. Oxidative Med. Cell. Longev. 2020; 2020: 1–16.

38. Abdulwahab RQ, Ali SM: Study in the protective effects of Cyanocobalamin treatment with pro-and antioxidant properties in chronic diseases. Oxidative Med. Cell. Longev. 2020; 2020: 1–16.

39. Abdulwahab RQ: Study in the protective effects of Cyanocobalamin on Methotrexate Induced Nephrotoxicity in rats. [Dataset]. 2022.

40. Abdulwahab RQ: Study in the protective effects of Cyanocobalamin on Methotrexate Induced Nephrotoxicity in rats. [Dataset]. 2022.
Open Peer Review

Current Peer Review Status: ✅ ✅

Version 2

Reviewer Report 07 November 2022
https://doi.org/10.5256/f1000research.139755.r154541

© 2022 Albanaa I. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

✅ Israa Albanaa

College of Pharmacy, Department of Pharmacology and Toxicology, University of Mosul, Mosul, Iraq

I have no further comments to make. You can accept the article for publication.

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Pharmacology and toxicology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 01 November 2022
https://doi.org/10.5256/f1000research.139755.r154540

© 2022 Alhaddad H. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

✅ Hasan Alhaddad

Moffitt Cancer Center, Toledo, OH, USA

The authors addressed my comments. I recommend this article for the publication.

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Neuropharmacology and oncology.
I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Israa Albanaa
Israa Albanaa

College of Pharmacy, Department of Pharmacology and Toxicology, University of Mosul, Mosul, Iraq

The paper did good lab work, but lack clarity and consistency of the work.

The citation is not accurate; the authors are citing the same paper which is under review.

In the results section, the presentation of the data is not clear, in particular the comparison between different groups. It would be better if the authors specify the compared group in the graphs so the reader can easily follow the results.

The discussion is not thorough; it would be more beneficial if they indicate the significance of the GSH and MDA so the reader could relate to the subject. I would recommend accepting the article after major corrections.

Please refer to the annotated pdf for additional notes, located here.

Is the work clearly and accurately presented and does it cite the current literature? Partly

Is the study design appropriate and is the work technically sound? Yes

Are sufficient details of methods and analysis provided to allow replication by others? Yes

If applicable, is the statistical analysis and its interpretation appropriate? Partly

Are all the source data underlying the results available to ensure full reproducibility?
Partly

**Are the conclusions drawn adequately supported by the results?**
Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Pharmacology and toxicology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

---

**Author Response 12 Oct 2022**

**rana qais, University of Baghdad, Baghdad, Iraq**

Thank you Dr. Israa for review my article, I made changes according to the notes that you sent on pdf and made a new version of the article.

About the (enzymatic method) section I wrote the procedure according to the journal instructions include the detail of the method used of the laboratory analysis.

I moved the figure (1) to the result section.

I changed the wrong references but the reference no 37,38,39 remain because these references include the data of result (data of GSH, MDA, urea and creatinine also the data of histopathological score and the other histological images) and refer to this data according to the journal instruction of and put this data on repository such as zenodo.

I can't change the method of comparing in the result section, I made it according to my supervisor in the study.

I added some explanation on the MDA and GSH in the discussion section

**Competing Interests:** No competing interests were disclosed.

---

**Reviewer Report 20 September 2022**

https://doi.org/10.5256/f1000research.136252.r149805

© 2022 Alhaddad H. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

© Hasan Alhaddad
Moffitt Cancer Center, Toledo, OH, USA

This interesting manuscript studies the possible effect of cyanocobalamin to protect from methotrexate induced nephrotoxicity. Authors showed that cyanocobalamin protected rat kidneys from methotrexate toxicity through reduction of oxidative stress, increase GSH and reduction in lesions.

This paper would be more valuable and interesting for readers if the authors revise the manuscript and address the following issues:

1. The overall writing style of the paper needs more attention. I would recommend to improve the writing and correct some grammar and punctuation errors.

2. The rationale for use of cyanocobalamin as a protective agent is not clear in the introduction. Is it utilized due to its antioxidant action? Please add some justification for why you chose this drug, i.e. add some previous studies that support its value as a possible protective agent.

3. In the methods, group II treatment is not clear. Please rephrase the treatment paradigm for this group.

4. The figures need more attention. Please make sure to have a unified x axis title. Please mention what the letters a, b, c, and d on the bars represent. Try to expand the figure legends to accurately describe the figure contents in details. Also, make sure to not cut part of the axis titles.

5. Again, revise all the writing. Please make sure to not miss words, for example: Although MDA levels in renal tissue homogenate (P<0.05) significantly in the IV & V groups, and decreased significantly in group VI compared to the the MTX treated group (P<0.01); In this case, is the MDA levels in renal tissue is higher or lower compared to IV and V groups. Please revise all.

Is the work clearly and accurately presented and does it cite the current literature?
Yes

Is the study design appropriate and is the work technically sound?
Yes

Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Yes

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
Yes

**Competing Interests:** No competing interests were disclosed.
Reviewer Expertise: Neuropharmacology and oncology.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 11 Oct 2022

rana qais, University of Baghdad, Baghdad, Iraq

Thank you Dr. Hasan for review of article, I made some change in the new version according to your notes.

The answers to your notes:

1. I made changes to these issues.

2. In this study, vit B12 was selected due to antioxidant action, according to previous animal studies, in which vitamin B12 can lower oxidative stress when used with different drugs such as tamoxifen and gentamycin. Vit B12 act as antioxidant by different mechanism: as a direct superoxide scavenger; in addition, may indirectly enhance ROS scavenging by protecting glutathione, which probably involves a complex network of processes that is not yet fully understood.

3. I rephrased (7 rats were treated with a single IP dose of methotrexate (MTX) (20 mg/kg) followed by single IP injection of 0.5 ml normal saline for 4 days. This group was served as positive control).

4. I added this explanation (Values expressed in non-identical letters (a, b, c, d) are significantly difference (p<0.05).

5. The MDA significant decrease (P<0.05) in group IV, V and highly significant decreased in group VI compared to MTX treated group II(P<0.01). I changed in the article (Although MDA levels in renal tissue homogenate (P<0.05) significantly decrease in the IV & V groups, and highly significant decrease in group VI compared to the MTX treated group (P<0.01).

Competing Interests: No competing interests were disclosed.
The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com